Literature DB >> 25400252

Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study.

Peng Liu1, Yingying Chen1, Bin Wang2, Fengmei Zhang1, Debao Wang1, Yangang Wang2.   

Abstract

OBJECTIVE: To investigate the effects of long-term effective control of serum uric acid on renal function in patients with type 2 diabetes and asymptomatic hyperuricemia.
METHODS: Application of randomized open parallel-controlled methods, a total of 176 patients with type 2 diabetes and asymptomatic hyperuricemia were selected, and was randomly divided into two groups for allopurinol or conventional treatments, respectively. Changes in urinary albumin excretion rate (UAER), the levels of serum creatinine and glomerular filtration rate (GFR) and the incidence of new-onset diabetic nephropathy (DN) and hypertension in patients before and after 3 years of treatment were measured and compared between groups.
RESULTS: There were no statistically significant difference in the baseline clinical characteristics of study participants between two treatment groups (P > 0·05 for all). After 3 years of treatment, compared to the conventional treatment, the allopurinol treatment was more effective in reducing serum uric acid, UAER, serum creatinine (P < 0·01 for all) and increasing GFR (P < 0·01). The intention-to-treat (ITT) analysis indicated that the incidence of new-onset DN and hypertension in the allopurinol group showed a declining trend compared to that in the conventional treatment group, despite a lack of significant difference (P > 0·05).
CONCLUSION: Long-term effective control of serum uric acid can decrease UAER and serum creatinine, increase GFR and may exert kidney protection effects in patients with type 2 diabetes and asymptomatic hyperuricemia.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25400252     DOI: 10.1111/cen.12673

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  35 in total

Review 1.  Fructose and uric acid in diabetic nephropathy.

Authors:  Petter Bjornstad; Miguel A Lanaspa; Takuji Ishimoto; Tomoki Kosugi; Shinji Kume; Diana Jalal; David M Maahs; Janet K Snell-Bergeon; Richard J Johnson; Takahiko Nakagawa
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

Review 2.  Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue.

Authors:  Chun Hu; Xiaoyan Wu
Journal:  Int Urol Nephrol       Date:  2019-08-28       Impact factor: 2.370

Review 3.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

Review 4.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors:  Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2018-02-27       Impact factor: 8.860

Review 5.  Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?

Authors:  Ambreen Gul; Philip Zager
Journal:  Curr Diab Rep       Date:  2018-03-01       Impact factor: 4.810

6.  Allopurinol protects human glomerular endothelial cells from high glucose-induced reactive oxygen species generation, p53 overexpression and endothelial dysfunction.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-11-01       Impact factor: 2.370

7.  [Diabetic nephropathy: current diagnostics and treatment].

Authors:  S Werth; H Lehnert; J Steinhoff
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

8.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

9.  Fructose tolerance test in obese people with and without type 2 diabetes.

Authors:  Ebaa Al-Ozairi; Christopher J Rivard; Laura Gabriela Sanchez Lozada; Miguel A Lanaspa; Petter Bjornstad; Danah Al Salem; Asma Alhubail; Amira Megahed; Masanari Kuwabara; Richard J Johnson; Reem A Asad
Journal:  J Diabetes       Date:  2019-09-18       Impact factor: 4.006

Review 10.  Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies.

Authors:  Petter Bjornstad; David Z Cherney; David M Maahs; Kristen J Nadeau
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.